Astrazeneca PLC 6-K, filed Apr 28, 2022
Astrazeneca PLC (AZN)
6-K
2022-04-28
For: 2022-04-28
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on April 28, 2022.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of April
2022
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Ultomiris approved in the US for adults with gMG
28 April 2022 07:00 BST
Ultomiris approved in the US for adults with
generalised myasthenia gravis
First and only long-acting C5 complement inhibitor to demonstrate
clinical improvement in patients with generalised myasthenia
gravis
Ultomiris showed early effect and lasting improvement in activities
of daily living and has potential to reduce treatment burden with
dosing every 8 weeks
Ultomiris (ravulizumab-cwvz) has been approved in the
US for the treatment of adult patients with generalised myasthenia
gravis (gMG) who are anti-acetylcholine receptor (AChR)
antibody-positive, which represents 80% of people living with the
disease.1-5
The approval by the Food and Drug Administration (FDA) was based on
positive results from the CHAMPION-MG Phase III trial, in
which Ultomiris was superior to placebo in the primary
endpoint of change from baseline in the Myasthenia
Gravis-Activities of Daily Living Profile (MG-ADL) total score at
Week 26, a patient-reported scale that assesses patients' abilities
to perform daily activities.1
This FDA action marks the first and only approval for a long-acting
C5 complement inhibitor for the treatment of gMG.
gMG is a rare, debilitating, chronic, autoimmune neuromuscular
disease that leads to a loss of muscle function and severe
weakness.6 The
diagnosed prevalence of gMG in the US is estimated
at approximately 90,000.7
Professor James F. Howard, Jr, MD, Department of Neurology at The
University of North Carolina School of Medicine and lead primary
investigator in the CHAMPION-MG trial said: "Despite recent
advances, managing gMG is complex. Earlier intervention can
preserve function and quality of life. This approval offers
patients, including those with milder symptoms, a long-acting C5
inhibitor with early onset and reliable efficacy."
Samantha Masterson, Chief Executive Officer, Myasthenia Gravis
Foundation of America (MGFA), said: "gMG takes a physical and emotional toll on those
living with the disease. We are grateful for continued innovation and
research into new treatment and dosing options to meet the needs of
more patients and reduce the treatment burden. With the approval
of Ultomiris, we're excited that MG patients now have another
option to consider as part of their personalised treatment
strategies that may offer more convenience and improve muscle
weakness."
Marc Dunoyer, Chief Executive Officer, Alexion, said: "Since
bringing forward the first complement inhibitor, we've continued to
listen to the community and focused innovation on the needs of gMG
patients. We're proud to deliver on this commitment with today's
approval. Ultomiris, the only long-acting C5 inhibitor, will
benefit a broader range of patients, including those with milder
symptoms. As presented at the 2022 American Academy of
Neurology Annual Meeting, Ultomiris has demonstrated clinical benefit through 60
weeks, with treatment every eight weeks, compared
to Soliris every two weeks."
In the trial, the safety profile of Ultomiris was comparable to placebo and consistent
with that observed in Phase III trials of Ultomiris in paroxysmal nocturnal haemoglobinuria
(PNH) and atypical haemolytic uraemic syndrome (aHUS). The
most common adverse reactions in patients
receiving Ultomiris were upper respiratory tract infection and
diarrhoea.1
Results from the CHAMPION-MG trial were recently
published online in NEJM
Evidence and presented at
the 2022 American Academy of Neurology Annual Meeting in
April.
Regulatory submissions for Ultomiris for the treatment of gMG are currently under
review with multiple health authorities, including in the European
Union (EU) and Japan.
Notes
gMG
gMG is a rare autoimmune disorder characterised by loss of muscle
function and severe muscle weakness.6
Eighty per cent of people with gMG are AChR antibody positive
meaning they produce specific antibodies (anti-AChR) that bind to
signal receptors at the neuromuscular junction (NMJ), the
connection point between nerve cells and the muscles they
control.2-6 This
binding activates the complement system, which is essential to the
body's defence against infection, causing the immune system to
attack the NMJ.6 This
leads to inflammation and a breakdown in communication between the
brain and the muscles.6
gMG can occur at any age, but it most commonly begins for women
before the age of 40 and for men after the age of
60.8-10 Initial
symptoms may include slurred speech, double vision, droopy eyelids
and lack of balance; these can often lead to more severe symptoms
as the disease progresses such as, impaired swallowing, choking,
extreme fatigue and respiratory failure.11,12
CHAMPION-MG
The global Phase III randomised, double-blind, placebo-controlled,
multicentre 26-week trial evaluated the safety and efficacy
of Ultomiris in adults with gMG. The trial enrolled 175
patients across North America, Europe, Asia-Pacific and Japan.
Participants were required to have a confirmed myasthenia gravis
diagnosis at least six months prior to the screening visit with a
positive serologic test for anti-AChR antibodies, MG-ADL total
score of at least 6 at trial entry and Myasthenia Gravis Foundation
of America Clinical Classification Class II to IV at screening.
Patients could stay on stable standard of care medicines, with a
few exceptions, for the duration of the randomised control
period.13
Patients were randomised 1:1 to receive Ultomiris or placebo for a total of 26 weeks. Patients
received a single weight-based loading dose on Day 1, followed by
regular weight-based maintenance dosing beginning on Day 15, every
eight weeks. The primary endpoint of change from baseline in the
MG-ADL total score at Week 26 was assessed along with multiple
secondary endpoints evaluating improvement in disease-related and
quality-of-life measures.
Patients who completed the randomised control period were eligible
to continue into an open-label extension period evaluating the
safety and efficacy of Ultomiris, which is ongoing.
Ultomiris
Ultomiris (ravulizumab-cwvz), the first and only
long-acting C5 complement inhibitor, offers immediate, complete and
sustained complement inhibition. The medication works by inhibiting
the C5 protein in the terminal complement cascade, a part of the
body's immune system. When activated in an uncontrolled manner, the
complement cascade over-responds, leading the body to attack its
own healthy cells. Ultomiris is administered intravenously every eight
weeks in adult patients, following a loading
dose.
Ultomiris is approved in
the US for the treatment of certain adults with
gMG.
Ultomiris is also approved
in the US, EU and Japan for the treatment of certain adults and
children with PNH.
Additionally, Ultomiris is approved in the US, EU and Japan for
certain adults and children with aHUS to inhibit
complement-mediated thrombotic microangiopathy.
As part of a broad development programme, Ultomiris is being assessed for the treatment of
additional haematology and neurology
indications.
Alexion
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca
focused on rare diseases, created following the 2021 acquisition of
Alexion Pharmaceuticals, Inc. As a leader in rare diseases for
nearly 30 years, Alexion is focused on serving patients and
families affected by rare diseases and devastating conditions
through the discovery, development and commercialisation of
life-changing medicines. Alexion focuses its research efforts on
novel molecules and targets in the complement cascade and its
development efforts on haematology, nephrology, neurology,
metabolic disorders, cardiology and ophthalmology. Headquartered in
Boston, Massachusetts, Alexion has offices around the globe and
serves patients in more than 50 countries.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1. Ultomiris (ravulizumab-cwvz)
US prescribing information; 2022.
2. Anil,
R., Kumar, A., Alaparthi, S., Sharma, A., Nye, JL., Roy, B.,
O'Connor, KC., Nowak, R., (2020). Exploring outcomes and
characteristics of myasthenia gravis: Rationale, aims and design of
registry - The EXPLORE-MG registry. J Neurol Sci. 2020 Jul
15;414:116830.
3. Oh
SJ., (2009). Muscle-specific receptor tyrosine kinase antibody
positive myasthenia gravis current status. Journal of Clinical
Neurology. 2009b Jun 1;5(2):53-64.
4. Tomschik,
M., Hilger, E., Rath, J., Mayer, EM., Fahrner, M., Cetin, H.,
Löscher, W., Zimprich, F., (2020). Subgroup stratification and
outcome in recently diagnosed generalized myasthenia gravis.
Neurology. 2020 Sep 8;95(10):e1426-e1436.
5. Hendricks,
TM., Bhatti, MT., Hodge, D., Chen, J., (2019). Incidence,
Epidemiology, and Transformation of Ocular Myasthenia Gravis: A
Population-Based Study. Am J Ophthalmol. 2019
Sep;205:99-105.
6. Howard,
J. F., (2017). Myasthenia gravis: the role of complement at the
neuromuscular junction. Annals of The New York Academy of Sciences,
1412(1), 113-128.
7. Westerberg,
E., Punga, A., (2020). Epidemiology of Myasthenia Gravis in Sweden
2006-2016. Brain and behavior. 2020 Nov;10(11):e01819.
8. Myasthenia
Gravis. National Organization for Rare Disorders (NORD).
Available here.
Accessed March 2022.
9. Howard, J.
F., (2015). Clinical Overview of MG.
Available here.
Accessed March 2022.
10. Sanders,
D. B., Raja, S. M., Guptill J. T., Hobson-Webb, L. D., Juel, V. C.,
& Massey, J. M., (2020). The Duke myasthenia gravis clinic
registry: I. Description and demographics. Muscle & Nerve,
63(2), 209-216.
11. Myasthenia Gravis
Fact Sheet. (2020, April 27). National Institutes of Neurological
Disorders and Stroke. Available here.
Accessed March 2022.
12. Ding,
J., Zhao, S., Ren, K., Dang, D., Li, H., Wu, F., Zhang, M., Li, Z.,
& Guo, J., (2020). Prediction of generalization of ocular
myasthenia gravis under immunosuppressive therapy in Northwest
China. BMC Neurology, 20(238).
13. ClinicalTrials.gov.
Safety and Efficacy Study of Ravulizumab in Adults With Generalized
Myasthenia Gravis. NCT Identifier: NCT03920293.
Available here.
Accessed March 2022.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
28 April
2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|